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Differential gene expression-based
connectivity mapping identified novel drug
candidate and improved Temozolomide efficacy
for Glioblastoma
Raghupathy Vengoji1, Pranita Atri1, Muzafar A. Macha1,2, Parthasarathy Seshacharyulu1, Naveenkumar Perumal1,
Kavita Mallya1, Yutong Liu3, Lynette M. Smith4, Satyanarayana Rachagani1, Sidharth Mahapatra1,5,6,
Moorthy P. Ponnusamy1,5, Maneesh Jain1,7, Surinder K. Batra1,5,7* and Nicole Shonka5,8*

Abstract
Background: Glioblastoma (GBM) has a devastating median survival of only one year. Treatment includes resection,
radiation therapy, and temozolomide (TMZ); however, the latter increased median survival by only 2.5 months in the
pivotal study. A desperate need remains to find an effective treatment.
Methods: We used the Connectivity Map (CMap) bioinformatic tool to identify candidates for repurposing based on
GBM’s specific genetic profile. CMap identified histone deacetylase (HDAC) inhibitors as top candidates. In addition,
Gene Expression Profiling Interactive Analysis (GEPIA) identified HDAC1 and HDAC2 as the most upregulated and
HDAC11 as the most downregulated HDACs. We selected PCI-24781/abexinostat due to its specificity against HDAC1
and HDAC2, but not HDAC11, and blood-brain barrier permeability.
Results: We tested PCI-24781 using in vitro human and mouse GBM syngeneic cell lines, an in vivo murine orthograft, and a genetically engineered mouse model for GBM (PEPG - PTENflox/+; EGFRvIII+; p16Flox/− & GFAP Cre +).
PCI-24781 significantly inhibited tumor growth and downregulated DNA repair machinery (BRCA1, CHK1, RAD51, and
O6-methylguanine-DNA- methyltransferase (MGMT)), increasing DNA double-strand breaks and causing apoptosis
in the GBM cell lines, including an MGMT expressing cell line in vitro. Further, PCI-24781 decreased tumor burden
in a PEPG GBM mouse model. Notably, TMZ + PCI increased survival in orthotopic murine models compared to
TMZ + vorinostat, a pan-HDAC inhibitor that proved unsuccessful in clinical trials.
Conclusion: PCI-24781 is a novel GBM-signature specific HDAC inhibitor that works synergistically with TMZ to
enhance TMZ efficacy and improve GBM survival. These promising MGMT-agnostic results warrant clinical evaluation.
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Key points
Identifying drugs via connectivity mapping and evaluation of these novel drugs can substantially reduce the
time to drug discovery.
PCI-24781 enhanced the efficacy of TMZ in GBM by
targeting DNA repair machinery.
Background
Glioblastoma (GBM) is the most common primary
brain malignancy in adults [1]. Current treatments have
not significantly improved the overall survival (OS) of
GBM patients in the past decade. Adding temozolomide
(TMZ) to radiation therapy (RT), only increased median
survival by 2.5 months overall [2], and by 6.4 months
in cases exhibiting epigenetic silencing of DNA repair
enzyme
O6-methylguanine-DNA-methyltransferase
(MGMT) [3]. TMZ and radiation-induced DNA damage are repaired by the DNA repair pathway, upregulated
in GBM [4]. Importantly, TMZ resistance is observed
even in the absence of MGMT, as Base Excision Repair
(BER), mismatch repair (MMR), and p53 mutations heavily influence TMZ sensitivity [5]. Thus, a drug targeting
the specific GBM signature agnostic of MGMT or DNA
repair enzyme status could lead to synergistic cytotoxicity with TMZ.
Histone acetylation is regulated by histone acetyltransferase (HAT) and histone deacetylase (HDAC), resulting
in chromatin structure alterations and increased accessibility to DNA for transcriptional activation or repression [6, 7]. Hyperacetylation of heat shock protein 90
(HSP90) alters its chaperone function and facilitates polyubiquitination and proteasomal degradation of HSP90
target proteins [8]. Pan-HDAC inhibitors panobinostat
and vorinostat/suberoylanilide hydroxamic acid (SAHA)
cause hyperacetylation of nuclear HSP90, degrading
DNA repair machinery proteins BRCA1, ATR, and CHK1
in breast cancer cells [9]. PCI-24781 increased the radiosensitization of pediatric GBM cells by decreasing the
DNA repair machinery proteins RAD51, Ku70, Ku86 and
DNA-PKcs [10]. In addition, HDAC inhibitors MS275
and TSA increased the sensitivity of TMZ and lomustine (CCNU) respectively, by inducing apoptosis in GBM
cells [11, 12]. Interestingly, the HDAC inhibitor RGFP109
increased the sensitivity of TMZ even in TMZ resistant
GBM cell lines by inhibiting the NF-kB pathway [13].
HDAC inhibitors significantly reduced GBM growth in
preclinical studies [14]. Romidepsin/FK228 significantly
reduced the tumor growth possibly by inhibiting PI3K/
AKT/mTOR pathways [15]. Disappointingly, in clinical
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trials, these drugs did not improve OS [16, 17] due to: (a)
lack of inhibitor selectivity, (b) poor blood-brain barrier
(BBB) permeability, (c) limited efficacy, and (d) high toxicity [18, 19]. We acknowledge that phase I clinical trials
are designed to demonstrate safety rather than efficacy
and that testing in recurrent tumors likely to be resistant
to TMZ may not be optimal for observing efficacy, however the toxicity and overall results of these studies did
not support further testing in GBM.
We used an in silico approach using Connectivity
Map (CMap), a tool developed by the BROAD Institute,
to identify drugs for repurposing based on their effect
on tumors’ genetic profiles [20]. We identified the BBBpermeable PCI-24781/abexinostat/THM-I-94, which
reverses the GBM gene signature by inhibiting HDAC1
and 2, while not affecting HDAC11. We evaluated its
anticancer activities using human and mouse GBM cell
lines in vitro and mouse orthograft and transgenic (PEPG
- PTENflox/+; EGFRvIII+; p16Flox/− & GFAP Cre +) in
vivo models. PCI-24781 enhanced apoptosis and downregulated DNA repair machinery (RAD51, CHK1, and
MGMT) in GBM cell lines in vitro. Further, PCI-24781
with TMZ decreased tumor burden and increased OS in
orthotopic murine models compared to vorinostat plus
TMZ. Importantly, PCI-24781 also decreased the tumor
volume in a 4.5-month-old genetically engineered mouse
(PEPG - PTENflox/+; EGFRvIII+; p16Flox/− & GFAP Cre
+). Our approach identified a novel, selective HDAC
inhibitor capable of potentiating the effects of TMZ in
GBM tumors, agnostic of DNA repair enzyme status.

Methods
In silico analysis
Identification of GBM datasets

Searching the NCBI repository Gene Expression Omnibus (GEO) datasets using the keywords “GBM” with
“Homo sapiens” and “tissue” identified 6183 studies. Four
datasets were selected for treatment-naïve tumors containing both normal (N) and tumor (T) samples within
the same dataset. GSE61335 (T- 48; N - 14), GSE35493
(T - 12; N - 8), GSE50161 (T - 34; N – 13) and GSE13276
(T – 5; N – 3) [21–24]. The datasets with mixed samples
were filtered to identify GBM specific samples. We considered 99 tumors and 38 normal or adjacent brain samples. To identify the differential gene expression in T vs.
N, a linear model (Limma package -R- Bioconductor) was
used for each of the studies separately [25].
Identification of potential therapeutics using CMap

Limma identified differentially expressed genes between
normal and tumor samples. The top 150 upregulated
and top 150 downregulated genes from each dataset
were subjected to a CMap query to identify negatively
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connected drugs able to reverse the GBM signature.
Comparing the negatively connected drugs identified
using each dataset led to 12 common drugs from which
PCI-24781 was chosen based on its selectivity, apoptotic
potential, and ability to cross the BBB.
In-silico identification of pathways affected by high scoring
HDAC inhibitors

The signatures of the high scoring HDAC inhibitors
(PCI-24781, vorinostat, belinostat) were assessed using
the web-server iLINCS [26]. Further, the web-based
search tool for interactions of chemicals (STITCH) was
used to assess chemical and protein interactions [27].
The top pathways from each drug network were analyzed
further.
GBM cell lines and cell cultures

GBM cell line cultures are described in Supplementary
Methods. Cell line validation was done at the University
of Arizona genetics core, Tucson, AZ. USA, by PCRbased short-tandem repeat (STR) analysis.
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Animals were maintained with food and water ad libitum and kept in 12 h alternating dark/light cycle. All animal experiments were carried out in accordance with U.S.
Public Health Service, “Guidelines for the care and use
of laboratory animals”, in accordance to ARRIVE guidelines and with approval of the UNMC Institutional Animal Care and Use Committee (IACUC) (UNMC IACUC
# 20–028-04 FC). We genotyped mice for EGFRvIII and
Cre positivity, p16 (point mutation in exon 2 of p16Ink4a)
and PTEN exon 5 deletions by PCR. Genotyping primers
and PCR conditions were followed as described by the
animal suppliers. Tumor growth was measured by MRI
bimonthly. Mice were sacrificed when they lost 20% body
weight or paralysis occurred and their brains were fixed
with 10% neutral-buffered formalin; brain tissues were
processed into paraffin blocks for hematoxylin, eosin, and
immunohistochemistry staining for lineage markers (glial
and neural). Our pathologist confirmed that these tumors
(PEPG - PTENflox/+; EGFRvIII+; p16Flox/− & GFAP Cre
+) were high-grade gliomas/GBM.
Syngeneic cell line development

Inhibitor

PCI-24781 was obtained from Xynomic Pharmaceuticals, USA, was dissolved in DMSO and aliquots stored in
− 20•C.
Combination index

The combination index/effect (CI) of TMZ and PCI24781 was determined using CompuSyn software [28]. A
CI value less than 1 supports synergy whereas > 1 confers
antagonist interaction.

Mice were sacrificed at ages 4 and 6 months (when mice
were weak/paralyzed), and a part of tumor tissue was
utilized for tumor characterization and RNA and protein isolation, and the rest of the tumor was used for cell
line generation as described earlier [30]. Cell line characterization (PTEN & p16- Genotyping PCR; EGFRvIII
– Immunoblotting with EGFRvIII specific antibody; p53
mutation – Sequencing), tumorigenic potential in vitro
and in vivo were done after 15 passages in cell culture.
Magnetic resonance imaging (MRI) and data analysis

Generation of the U-118MG brain tumor xenografts

All animal experiments were reviewed and approved
by the Institutional Animal Care and Use Committee.
U-118MG tumor xenografts were generated as described
with slight modifications [29] (see Supplementary
Methods).
GBM mouse model development

A transgenic mouse expressing Cre recombinase
under the control of the astrocyte-specific human
GFAP promoter (B6.Cg-Tg(GFAP-cre) 8Gtm/Nci (B6);
strain number 01XN3), EGFRvIII mouse (CAG-LSLEGFRvIII; strain number 01X68) were obtained from
the NCI mouse repository. PTEN mouse (B6.129S4Ptentm1Hwu/J; strain number 006440) was obtained
from Jackson Laboratory and p16 mouse (EM:00435
FVB;129P2-Cdkn2atm1.1Brn/Cnrm; strain number
EM:00435) obtained from the European Mouse Mutant
Archive (EMMA).

MRI was performed on a 7 Tesla scanner (Bruker PharmaScan, Billerica, MA) operated by ParaVision 7 with a
quadrature RF coil for signal transmission and reception.
T2-weighted images were acquired at the axial direction
using a TuborRARE sequence with the following parameters: TR/TE = 4200/48 ms, RARE factor = 8, Averaging = 4, Matrix size = 256 × 192, FOV = 20 × 20 mm2,
slice number = 21, slice thickness = 0.5 mm. T1-weighted
MRI was performed using a MDEFT sequence with 4 segments, segment TR = 2600 ms, TE = 2.2 ms, TI = 950 ms,
flip angle = 30°, Averaging = 3, Matrix = 256 × 256,
FOV = 20 × 20 mm2, slice number = 15, slice thickness = 0.5 mm. The T1- and T2-weighted MRI was followed by tail vein injection of gadolinium (MultiHance,
Bracco Diagnostics) at 0.1 mmol/kg. After 15 min of gadolinium injection, the mouse was scanned using T1- and
T2-weighted MRI again. Mice were anesthetized using
1.5% isoflurane carried by 1 L/min oxygen. The breathing rate and body temperature were monitored during
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scanning. The isoflurane was continuously adjusted to
maintain the breathing rate between 40 and 80 bpm.
Region-of-interest (ROI) analysis in image J (imagej.
nih.gov/ij/) was used to measure tumor volumes. The
post-contrast T1-weighted images (T1post) were primarily used for the measurements with pre-contrast
T1-weighted (T1pre) and T2-weighted images as
references.
Statistical analysis

The in vitro assays were repeated at least three times and
are presented as mean values ± SD. ANOVA was used to
evaluate differences between groups, and Tukey’s method
was used to adjust for multiple comparisons. Photon
data on Day 32 were analyzed on the natural log scale to
meet model assumptions. Pairwise comparisons between
control and treatment groups were adjusted for multiple comparisons with Dunnett’s photon data method.
Overall survival was estimated using the Kaplan-Meier
method, and groups were compared using the log-rank
test. Mice alive at the end of the study were treated as
censored. P-values less than 0.05 were considered as statistically significant. Statistical analyses were performed
using SAS 9.4 (SAS Institute Inc., Cary, NC).

Results
In silico connectivity mapping (CMap) identified potential
drugs for GBM

Initial analysis of GEO datasets identified 18,457 human
GBM studies, of which 6183 were tissue-based and further restricted for 1) treatment-naïve tumor samples (to
preserve native tumor gene expression profile) and 2)
common dataset expression profile of normal (N) and
tumor (T) (to fit a linear model). Four datasets were
selected: GSE61335 (T- 48; N - 14), GSE35493 (T - 12; N
- 8), GSE50161 (T - 34; N - 13) and GSE13276 (T - 5; N 3) for 99 tumors and 38 normal or adjacent normal brain
samples.
To identify differential gene expression in T vs. N, a linear model (Limma package) was used for each study [25].
Those genes were matched to gene expression profiles
from over 2300 drugs in CMap Fig. 1A. Five-hundred
twelve drugs were highly negatively connected to each
dataset (Fig. 1B), most of which were HDAC inhibitors.
We then assessed CMap scores for connections to gene
signatures for all twelve drugs common to the four datasets from the updated CMap data (Fig. 1C, D & Table S1).
The highest scoring cluster (Fig. 1D) included PCI-24781,
vorinostat, and belinostat. A drug-protein network using
the web-server iLINCS and STITCH identified specific
pathways affected by each drug (Fig. 2A - C). Unlike
vorinostat and belinostat, the PCI-associated gene network showed significant differences in DNA binding and
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apoptotic signaling, corroborated by western blot analysis (Fig. 2A – C & F).
Further, Gene Expression Profiling Interactive Analysis (GEPIA) [31] comparing normal (207) and GBM
(163) samples revealed significant upregulation of DNA
repair machinery genes BRCA1, CHK1, RAD51, and
Ku70 in GBM (p < 0.01) (Fig. 2D). In MGMT expressing
U-118MG cells, PCI-24781 potentially downregulated
DNA repair machinery proteins MGMT, RAD51, and
CHK1 compared to pan-HDAC inhibitors, suggesting
that relative TMZ resistance (Fig. 2E) -possibly due to a
higher expression of these DNA repair enzymes - may be
overcome by PCI-24781.
GEPIA also revealed a specific GBM HDAC signature: significant upregulation of HDAC1 and HDAC2
with concomitant downregulation of HDAC 11 (p < 0.01)
(Fig. 3A). PCI and vorinostat were found to concurrently
inhibit HDAC 1 and 2, but not HDAC11 (Fig. 3B- H,
Table S2). As PCI-24781 had never been evaluated in
adult GBM, exhibits inhibitor selectivity, and effectively
downregulates DNA repair enzymes, we elected to further study and characterize its effects.
PCI-24781 inhibits GBM cell proliferation in vitro

We evaluated the efficacy of PCI-24781 on GBM cell
proliferation with different genetic backgrounds: U87
(p53 WT and MGMT methylated), U251 (p53 mutated
and MGMT methylated), and U-118MG (p53 mutated
and MGMT un-methylated) using an MTT assay. The
inhibitory concentration (IC25) values (0.5–1.25 μM)
were similar among these cell lines, and its anti-tumorigenic potential was not altered by p53 mutational status
(Table S3). Enticingly, PCI-24781 was equally effective in
MGMT-expressing U-118MG cells and relatively chemoresistant EGFRvIII-expressing cells (Fig. S1A & B; Table
S3) [32]. Further, PCI-24781 decreased cell proliferation
of our mouse syngeneic cell line (EGFRvIII+; p16Flox/Flox
& GFAP Cre +), resistant to TMZ, in a dose-dependent
manner (Fig. S1C & D).
PCI-24781 decreases in vitro tumorigenicity of GBM cells

We analyzed PCI-24781 on GBM cell in vitro tumorigenicity using colony formation assay. Treatment of U87,
U87EGFRvIII, U251, U251EGFRvIII, and U-118MG cells
with PCI-24781 resulted in significant suppression of
colony formation compared to vehicle control (p < 0.001)
(Fig. 4A & B) and resulted in 71 ± 12; 72 ± 12; 84 ± 3;
89 ± 2; 92 ± 1 percentage decrease in colony formation in
these cell lines respectively. Though some colonies were
resistant to monotherapy, combination treatment completely abrogated GBM colony formation. PCI-24781 significantly decreased the in vitro tumorigenic capability of
U-118MG cells compared to TMZ (p < 0.0001) (Fig. 4A &
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Fig. 1 Drug classes negatively connected to the GBM signature. A Pipeline for drug discovery using connectivity mapping. B Drug classes with
negative connectivity scores (> − 80). HDAC inhibitors were found to be the most enriched class. C The negatively connected drugs from CMap
compared with a four-way Venn diagram. The 12 drugs negatively connected to all datasets were then studied more closely. D Top 12 drugs
exhibiting negative connection with GBM signature common across the four datasets

B). These results support the anti-tumorigenic potential
of PCI-24781 on MGMT expressing GBM cells. Further,
combining PCI-24781 + TMZ significantly decreased the
tumorigenic potential of EGFRvIII+; p16Flox/Flox & GFAP
Cre + syngeneic cell lines (Fig. S2A & B).
Effect of PCI-24781 on GBM cell viability

We next investigated the correlation between PCI’s demonstrated ability to suppress tumor growth and apoptosis. Our PI/Annexin V apoptosis assay on U-118MG

cells revealed that single-agent PCI-24781 induced
significant cell death (p < 0.0001). The percentages of
early and late apoptotic cells together were (4.8 ± 0.11,
8.6 ± 0.6, 22.5 ± 0.5 & 52.1 ± 2.2) respectively for invehicle control, TMZ, PCI-24781 and TMZ + PCI-24781
treated U-118MG cells (Fig. 4C & D). To validate this
apoptotic effect, we analyzed markers cleaved caspase
3 and cleaved poly ADP ribose polymerase (PARP), a
DNA repair enzyme, in all aforementioned cell lines.
We observed augmented cell death due to apoptosis in
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Fig. 2 PCI-24781 potentially decreases the DNA repair machinery and activates apoptotic signaling (A-C) Pathways: The web-based iLINCS server
was used to assess the associated signatures for each of the top 3 scoring drugs. Pathways affected by PCI-24781 (A), belinostat (B), and vorinostat
(C). Interestingly, PCI-24781 has a unique signature when compared to pan-HDAC inhibitors and specifically impacts apoptotic signaling. D DNA
repair machinery expression in GBM Using GEPIA on 163 GBM tumors (red) and 207 controls (black) show that DNA repair machinery genes BRCA1,
RAD51, CHK1, and Ku70 are significantly upregulated in GBM when compared to control (p < 0.01). E PCI-24781 effectively decreases the DNA repair
machinery in U-118MG GBM cells. U-118MG cells were treated with 1.5 μM of HDAC inhibitor for 48 h, and lysates were analyzed for DNA repair
machinery proteins by immunoblotting. The extent of acetylation of α tubulin supports the efficacy of PCI-24781. DMSO served as vehicle control.
F U-118MG cells were treated with 1.5 μM of HDAC inhibitor for 48 h, and lysates were analyzed for apoptotic markers cleaved PARP (CST- 9541;
recognize cleaved PARP, not total) and cleaved caspase 3

PCI-24781 treated cells and synergy with TMZ (Fig. 4C E and Fig. S3A & S3B).
HDAC inhibitors induce cell death in multiple ways,
possibly by upregulating pro-apoptotic proteins,
decreasing the anti-apoptotic proteins, and inducing reactive oxygen species (ROS) [33]. ROS production results in lipid peroxidation products like

4-hydroxynonenal (4-HNE), a biomarker of oxidative
stress [34]. We checked pro-apoptotic protein BAX and
anti-apoptotic protein BCL-2 expression in PCI-24781
treated U-118MG cells. PCI-24781 increased the expression of BAX while decreasing BCL2 expression at 48 h
(Fig. 5A). Next, to test if PCI-24781 induced ROS production, followed by DNA damage resulting in cell death,
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Fig. 3 PCI-24781 does not inhibit HDAC11. A GEPIA on HDAC expression in GBM (Sample size; Control (Black) (n = 207) and GBM (Red) (n = 163)).
HDAC1 and 2 are significantly upregulated, while HDAC11 is downregulated (p < 0.01). GEPIA- Gene Expression Profiling Interactive Analysis. B–H
HDAC1, HDAC2, and HDAC11 assay were done by Reaction Biology Corp. using fluorogenic peptide from p53 residues 379–382 (RHKK(Ac)AMC)
[substrates for HDAC1 and 2] and trifluoroacetyl lysine [substrate for HDAC11]. PCI-24781 and vorinostat inhibit HDAC1 and 2 but do not have an
inhibitory effect on HDAC11, as do belinostat and TSA. B, D & F HDAC reference compound TSA were tested in a 10 dose IC50 with 3 fold serial
dilution starting at 10 μM (C) HDAC1, (E) HDAC2 and (G) HDAC11. (H) IC50 values are summarized in table.*Empty cells indicate no inhibition or
compound activity that could not fit an IC50 curve. TSA-Trichostatin
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Fig. 4 PCI-24781 suppresses GBM cell proliferation and induces apoptosis. Cells were seeded in DMEM complete media. After 12 h, cells were
treated with vehicle control, IC25 of TMZ, IC25 of PCI-24781, or TMZ and PCI-24781 for 48 h, and cultured up to 2 weeks in drug-free DMEM complete
media. Colonies were fixed with methanol and stained with crystal violet, then dissolved in 10% acetic acid, and absorbance measured at 595 nm.
Results represented as difference in percentage colony formation. A Representative images of colony formation assay. B Mean percent difference
in colony formation in different drug treatment groups from three independent experiments. ANOVA was used to compare the colony formation
variable on the natural log scale. Pairwise comparisons are adjusted with Tukey’s method. ‘*’ p ≤ 0.0001; ‘$’ p ≤ 0.01; ‘#’ p < 0.001 “*” significantly
different compared to vehicle control; “$” significantly different compared to TMZ; “#” significantly different compared to PCI-24781. C-E PCI-24781
induces apoptosis in GBM cells. C Representative Annexin V and PI staining of vehicle control, TMZ, PCI, and TMZ + PCI treated U-118MG cells.
D Quantification (percentage of ) early and late apoptotic cells. Early and late apoptosis was compared between groups using ANOVA. Pairwise
comparisons are adjusted with Tukey’s method. ‘*’ p < 0.03; ‘$’ p < 0.0001; ‘#’ p < 0.0001. “*” significantly different compared to vehicle control; “$”
significantly different compared to TMZ; “#” significantly different compared to PCI-24781. E U87, U87EGFRvIII, U251, U251EGFRvIII, and U-118MG
cells were incubated with the drugs mentioned above for 48 h, and lysates were subjected to immunoblot analysis to identify the levels of
apoptotic proteins, cleaved PARP, and cleaved caspase-3

we measured ROS production using 2′,7′-dichlorofluorescein diacetate (DCFDA) [35]. ROS induction was
seen in PCI-24781-treated GBM cells within 30 min
and peaked at 6 h (Fig. 5B). These results were further

validated by immunoblotting with lipid peroxidation
marker 4-HNE. Our immunoblotting results support
ROS generation, and 4-HNE adduct formation in PCI24781 treated GBM cells (Fig. 5C). To understand the
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Fig. 5 PCI-24781 displays a direct apoptotic effect in GBM cells. A U-118MG cells were treated with 1.25 μM PCI-24781 for 24 and 48 h, and cell
lysates were analyzed for pro and anti-apoptotic markers by western blotting. B-D PCI-24781 induces ROS generation in GBM cells. B U-118MG
cells were treated with vehicle control, TMZ, PCI-24781 or TMZ, and PCI-24781 combination for the indicated times. After incubation, media were
removed, and cells rinsed with Krebs-Ringer buffer and stained with 10 μM DCF-DA at 37•C for 30 min in the dark. Finally, cells were washed in
buffer, and fluorescent images were taken, and the representative images are shown. Scale bar 400 μm. C U-118MG cells were incubated with drugs
for 6 h, and lysates were analyzed for lipid peroxidation marker 4-HNE by immunoblotting. D U-118MG cells were incubated with vehicle control,
PCI-24781, PCI-24781 + NAC (15 mmol/L), or 2 h pre-treatment with NAC, followed by PCI-24781 for 48 h, and lysates were analyzed for apoptotic
markers. Acetylation of α-tubulin serves as the marker for HDAC inhibitor PCI-24781 treatment. ROS- reactive oxygen species; NAC- N-acetylcysteine

consequence of ROS induction by PCI-24781 on cell
death, U118-MG cells were treated with PCI-24781 in
the presence and absence of ROS scavenger N-acetylcysteine (NAC) and the apoptotic marker cleaved PARP
was analyzed. NAC (15 mmol/L) did not alter the extent
of cell death, although two hours of NAC exposure before
PCI-24781 was slightly protective (Fig. 5D). These results
indicate that ROS production facilitates cell death but is
not solely responsible for PCI-24781 mediated toxicity.
Effect of PCI-24781 on DNA repair machinery

Pan-HDAC inhibitors panobinostat and vorinostat hyperacetylate nuclear HSP90, resulting in

proteasomal degradation of DNA repair machinery
proteins BRCA1, ATR, and CHK1 in breast cancer
cells [9]. In contrast, Kachhap et al. demonstrated
that downregulation of DNA repair genes BRCA1,
CHK1, and RAD51 occurs at a transcriptional level
upon HDAC inhibition [36]. Our western blot analysis
showed that PCI-24781 potentially reduced the DNA
repair machinery proteins RAD51, CHK1, and BRCA1
in various human GBM cells (Fig. 6A). To identify
whether this degradation occurs at the transcriptional vs. the post-translational level, we performed
Quantitative Real-Time-PCR on reverse-transcribed
cDNA obtained from PCI-24781 treated U-118MG
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Fig. 6 PCI-24781 decreases DNA repair machinery at the transcriptional level in GBM cells. A Cells were incubated with IC25 of TMZ, IC25 of
PCI-24781 or combination for 48 h, and lysates were analyzed for RAD51, CHK1, and BRCA1 levels by immunoblotting. β-actin serves as a loading
control. B Real-Time qRT-PCR for RNA expression of BRCA1, CHK1, RAD51, and Ku70 normalized to GAPDH in drug-treated (as given in (A)) U-118MG
cells. The qPCR data is analyzed using the 2-∆∆CT method. ANOVA compared the ∆Ct values between groups, and Tukey’s method was used to adjust
for multiple comparisons. Results are given as fold change between groups with 95% confidence intervals. ‘*’ p < 0.01; ‘#’ p ≤ 0.01.”*” significantly
different from vehicle control; “#” significantly different from TMZ. Data presented as mean +/− SD, experiments done in triplicate. C Mouse
syngeneic cell lines were treated with 1.5 μM PCI-24781 for 48 h, and cell lysates were analyzed for DNA repair machinery and apoptotic marker by
western blotting. ‘–‘ and ‘+’ signs indicate vehicle and PCI-24781 treatment, respectively

cells. We observed that PCI-24781 treatment significantly reduced the BRCA1, CHK1, RAD51, and Ku70
mRNA levels (p < 0.01) (Fig. 6B). We also validated
the effect of PCI-24781 as a monotherapy to induce
cell death and abrogate DNA repair protein in our
in-house generated mouse syngeneic GBM cell lines.

We observed that PCI-24781 reduced the expression
of Rad51, CHK1 while activating γH2AX and caspase 3 (Fig. 6C). Our results suggest that PCI-24781
can induce cell death in syngeneic cell lines irrespective of the mutational status of p53, EGFRvIII, and p16
deletion.

Vengoji et al. J Exp Clin Cancer Res

(2021) 40:335

Page 11 of 17

Fig. 7 PCI-24781 induced DNA DSB (γH2AX foci) in GBM cells. A GBM cells were incubated with vehicle control, TMZ, PCI-24781, and combination
for 48 h and probed with γH2AX (phospho S139) antibody, and nuclei counterstained with DAPI. Representative immunofluorescence images are
shown. Scale Bar 5 μm. B Quantitative measurement of γH2AX staining represented as an arithmetic mean intensity per cell. Staining data were
compared between control and treatment groups using one-way ANOVA. Pairwise comparisons between control and treatment groups were
adjusted for multiple comparisons with Tukey’s method. “*” significantly different compared to vehicle control; ‘*’ p < 0.05; ‘$’ p < 0.001; ‘#’ p < 0.0001.
“$” significantly different compared to TMZ; “#” significantly different compared to PCI-24781. C Immunoblot analysis of γH2AX (phospho S139) levels
in vehicle or drug-treated GBM cells. DNA DSB- DNA double-strand break

PCI-24781 induces DNA double-strand breaks in GBM cells

H2AX is the key enzyme involved in the DNA damage repair process and is phosphorylated at the serine-139 during DNA damage [37]. We analyzed the
phospho-histone H2AX (Ser139) staining to indicate
DNA double-strand breaks (DSBs) in TMZ and PCI24781 treated GBM cells. We used confocal microscopy to identify the γ-H2AX foci formation upon
drug treatment. As expected, the alkylating agent
TMZ induced DNA damage in GBM cells (Fig. 7A).
Interestingly, PCI-24781 alone also induced DNA

damage, as evidenced by cells positive for γ-H2AX
and enlarged nuclei (Fig. 7A and Fig. S4). Our quantitative analysis revealed that PCI-24781 treatment
resulted in 83, 86, 130, 283, and 136% γ-H2AX arithmetic mean intensity increases in U87, U87EGFRvIII,
U251, U251EGFRvIII, and U-118MG cells respectively when compared to untreated control (Fig. 7B).
This effect was significantly augmented by the addition of TMZ (p < 0.001) (Fig. 7B). These results
were further confirmed by γ-H2AX immunoblotting
(Fig. 7C).
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PCI-24781 is effective in MGMT expressing GBM
orthografts and a genetically engineered mouse model
for GBM

Although PCI-24781 decreases the viability of human
GBM cell lines in vitro, the in vivo system presents a
restrictive drug accessibility barrier via the BBB for brain
tumors. To study the efficacy of PCI-24781 in vivo, we
used U-118MG orthografts. We intracranially injected
U-118MG cells transfected with GFP-luciferase into
athymic nude mice. After a week, tumor growth was
measured by substrate CycLuc1 i.p. injection, followed
by Bioluminescence imaging (BLI). Based on tumor
size, animals were randomized to treat i) vehicle control,
ii) TMZ, iii) PCI-24781, iv) vorinostat, or v) combination TMZ + PCI or vi) TMZ + vorinostat. IVIS imaging
showed the tumor growth decreased by 86, 72, 17, 97
and 80% in TMZ, PCI-24781, vorinostat, TMZ + PCI
and TMZ + vorinostat groups, respectively compared to
control (Fig. 8A & B). TMZ + PCI significantly decreased
the tumor burden compared to control (p < 0.05) (Fig. 8A
& B) and significantly increased the OS (p < 0.0001)
(Fig. 8C), supporting BBB permeability of PCI-24781 and
synergy with TMZ. TMZ + PCI-24781 treated mice were
sacrificed after 92 days, and vehicle-treated, and other
drug-treated group mice were sacrificed when they were
weak. Figure 8D (Fig. S5) shows the pre-treatment T1
post-contrast images of a PEPG (PTENflox/+; EGFRvIII+;
p16Flox/− & GFAP Cre +) 4.5 month old mouse. Tumor
is close to the hypothalamus and thalamus, denoted
by arrows (Fig. 8D). The T1 post-contrast images after
4 weeks of PCI-24781 are shown in Fig. 8E. Tumor volume decreased from 7.1 mm3 to 5.2 mm3 on ROI analysis,
a 26.4% decrease.

Discussion
GBM has a dismal 5-year survival of 10% [38]. Treatment
includes surgery, RT, and TMZ [38]. Response to TMZ is
curtailed by DNA repair mechanisms rendering alkylators less effective [39]. Unattended DNA DSBs can lead
to genomic instability and cell death. There are two major
pathways by which DNA DSB repair occurs: Homology–
directed repair (HDR/HR) and non-homologous endjoining (NHEJ). TMZ is an alkylator that induces three
common DNA lesions N3-methyladenine (N3-meA),
N7-methylguanine (N7-meG), and O6-methylguanine
(O6-meG) [40]. N3-meA and N7-meG are primarily
repaired by the BER pathway, while O6-meG is repaired
by MGMT [40]. Though much clinical focus is on
MGMT methylation, TMZ-induced O6-meG DNA damage is minimal (~ 5 to 10%), and the remaining ~ 90%
are at N3-meA and N7-meG [41]. TMZ resistance is also
caused by alkylpurine-DNA-N-glycosylase (APNG), a
BER enzyme, in T98G GBM cells [42]. Silencing of BER
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enzyme apyrimidinic/apurinic endonuclease/redox factor-1 sensitized T98G cells to TMZ [43]. Adimoolam
et al. provided direct evidence for PCI-24781, which
decreased HR activity in Chinese hamster ovary cells,
possibly by downregulating RAD51 [44]. Additionally,
HDAC inhibition increased the synthetic lethality of the
PARP inhibitor veliparib/ABT-888 in prostate cancer
cells by inhibiting HR DNA repair signaling [45].
This study used an agnostic approach to drug identification by starting with an in silico method applying
the tool CMap, to identify drugs for repurposing based
on their genetic profiles for GBM. Utilizing the GEPIA
database and further scrutinizing inhibitor selectivity, we
selected PCI-24781/abexinostat, which effectively targets GBM cells. Our GEPIA database analysis revealed
that HDAC11 is significantly downregulated in GBM.
Tumor growth rates of murine lymphoma (EL4) and pancreatic adenocarcinoma cell lines (Panco) were significantly higher in HDAC11 knock out C57BL/6 mice [46],
and myeloid-derived suppressor cells (MDSCs) isolated
from HDAC11 knock out mice seem more suppressive
than the WT MDSCs. Moreover, loss of HDAC11 function induces the immunosuppressive interleukin-10 [46].
PCI-24781 does not inhibit HDAC11, as do belinostat
and trichostatin A. Certainly, PCI-24781 displayed strong
cytotoxic effects on neuroblastoma cell lines with an IC50
of less than 200 nanomolar while other pan HDAC inhibitors (sodium butyrate, SAHA and valproic acid) had IC50
values in the ranges of micromolar to millimolar [47].
We evaluated the anticancer activities of PCI-24781
alone and with TMZ. PCI-24781 significantly inhibited proliferation and tumorigenicity while augmenting
apoptosis via downregulation of DNA repair machinery
proteins (BRCA1, RAD51, CHK1) in GBM cells. In vivo,
PCI-24781 effectively crossed the BBB and efficiently
decreased tumor burden in orthotopic GBM xenografts
alone and with TMZ.
In prior studies, vorinostat displayed anti-proliferative effects in glioma cells in a p53 independent manner
[48]. Our MTT assays also support PCI-24781 GBM cell
growth inhibition irrespective of p53 status. Furthermore, its anti-tumorigenic potential was unaffected by
MGMT and EGFRvIII over-expression.
Vorinostat induces ROS production in a concentrationdependent manner, and [49] vorinostat-mediated cell
death was inhibited by 50% with antioxidant NAC treatment [49]. Our studies showed PCI-24781 induced ROS
production in GBM cells, but NAC treatment did not
attenuate GBM cell death, suggesting ROS generation is
not entirely responsible for PCI-24781 induced cytotoxicity as it may be with vorinostat.
Hyperacetylation of HSP90 changes its chaperone function and facilitates polyubiquitylation and proteasomal
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Fig. 8 PCI-24781 and TMZ in combination decrease tumor burden in vivo. A Animals treated with both drugs had more significant decreases
in tumor burden. U-118MG luciferase transfected cells (1X10^5 cells in 3 μl of PBS) were intracranially injected into 4 to 6 week-old mice. After
10 days, BLI measured tumor growth, and animals were randomized into 6 groups and treated with vehicle control, TMZ (25 mg/kg BW), PCI-24781
(12.5 mg/kg BW, BID), vorinostat (100 mg/kg/BW), PCI-24781+ TMZ or vorinostat + TMZ for 5 days a week. Qualitative BLI imaging is shown in (A),
and quantitative measurements (total photon flux, photons/second) of the BLI from the tumor is shown in (B). ‘*‘p < 0.05 .“*” significantly different
compared to vehicle control. BLI- bioluminescence imaging. Data presented as mean +/− SEM and analyzed using the natural log of photon
levels on Day 32 compared to control and treatment groups using one-way ANOVA. Pairwise comparisons were adjusted for multiple comparisons
with Dunnett’s method. C PCI-24781 improved survival over vorinostat, and PCI + TMZ significantly increased overall survival. Overall survival was
estimated using the Kaplan-Meier method, and groups were compared using the log-rank test. Mice alive at the end of the study were treated as
censored. ‘*‘p < 0.0001. “*” significantly different compared to vehicle control. D & E PCI-24781 decreases tumor burden in the GBM mouse model.
MRI was done on a 7 Tesla scanner. (Bruker PharmaScan, Billerica, MA) operated by ParaVision 7 with a quadrature RF coil for signal transmission and
reception. MRI on GBM mouse (PEPG - PTENflox/+; EGFRvIII+; p16Flox/− & GFAP Cre +). D; (i)-(vi) shows the pre-treatment axial T1post images of a
mouse brain in rostral-caudal direction. E (i)-(vi) Axial T1post images acquired after 4 weeks of 5-days weekly PCI-24781 (12.5 mg/kg BW, BID, PO)

degradation of HSP90 target proteins [8]. Pan-HDAC
inhibitors panobinostat and vorinostat hyperacetylate
nuclear HSP90, which degrades DNA repair machinery proteins BRCA1, ATR, and CHK1 in breast cancer

cells [9]. However, downregulation of DNA repair genes
BRCA1, CHK1, and RAD51 occurs at the transcriptional
level through a decrease in the recruitment of transcription factor E2F1 upon HDAC inhibition [36]. GEPIA
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database analysis revealed RAD51, CHK1, BRCA1, and
Ku70 are upregulated in GBM and that higher expression of RAD51 [50] and BRCA1 [51] were associated
with shorter survival. Our western blot analysis on PCI24781 treated GBM cell lysates showed decreased expression of BRCA1, CHK1, and RAD51. Further, quantitative
real-time-PCR analysis on BRCA1, CHK1, and RAD51
in PCI-24781 treated GBM cells revealed that silencing
occurs at the transcriptional level.
DNA DSBs in chromatin induce phosphorylation at
serine 139 of the histone H2A variant, H2AX, producing γ-H2AX [52]. γ-H2AX generation is essential to
recruit several DNA repair proteins, which inhibit cell
cycle progression by regulating cell cycle checkpoints
[53]. HDAC inhibitors added to radiation increase the
duration of γ-H2AX and radiosensitivity of prostate
and melanoma cells [53]. Of note, BRCA1 and BRCA2
proteins colocalize with RAD51, essential for HR repair
of DNA DSBs [54]. PCI-24781 treatment decreased
RAD51 levels and the HR activity in Chinese hamster
ovary cells [44]. Further, HDAC inhibition increased
chemosensitivity of prostate cancer to the PARP inhibitor veliparib/ABT-888 by inhibiting HR DNA repair
signaling [45]. A recent study shows that increased
DNA damage is associated with enlarged nuclei [55].
Our studies showed that PCI-24781 decreases the
RAD51 and BRCA1 levels and enhances γ-H2AX formation, nuclei enlargement, and apoptotic effects of
TMZ.
Deutsch et al. demonstrated that (14C)- PCI-24781
was found in the cerebrum, cerebellum, plasma, and all
tissues after IV administration; evidence for BBB penetration [56], further supported by our BLI data. Orally
administered PCI-24781 plus TMZ treatment potentially inhibited the growth of intracranial U-118MG
GBM xenografts compared to vorinostat plus TMZ.
Further, our MRI of a PCI-24781 treated GBM mouse
model also supports its anti-tumorigenic potential.
Intraperitoneal vorinostat decreased tumor burden
in a murine glioma model but only increased median
survival by 8 days [48]. Two other preclinical studies
with vorinostat displayed better efficacy; however, they
injected vorinostat intracranially [57, 58], another route
that does not mimic normal human drug administration. Thus, ineffective drug distribution may be one reason behind the limited clinical efficacy of vorinostat in
GBM patients. However, in our study, lower concentrations of PCI-24781 (12.5 mg/kg BW, two times per day,
5 days/week, given via oral gavage), provided greater
efficacy with less toxicity. While many HDAC inhibitors are cardiotoxic, leading to ventricular arrhythmias
and QT/QTc prolongation [59], PCI-24781 was well

Page 14 of 17

tolerated in clinical study, with only one patient experiencing grade 3 QTc prolongation phase II PCI-24781
[59].

Conclusion
Utilizing in silico analysis to efficiently decrease drug
screening time, we identified PCI-24781 based on its
unique inhibitor selectivity and apoptotic potential.
PCI-24781 displayed strong anti-proliferative effects on
GBM cells in vitro, irrespective of the mutational profile. Additionally, it enhanced TMZ-induced apoptosis,
possibly by increasing γ-H2AX formation through the
downregulation of DNA DSB repair proteins. In vivo,
PCI-24781 decreased the tumor burden of GBM orthografts and in a GBM mouse model. These exciting
results provide the rationale for a clinical trial combining PCI-24781 with TMZ to improve survival in all
GBM patients, agnostic of mutational profile.
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